Measure (mathematics)

ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024

Retrieved on: 
星期一, 五月 6, 2024
Charcot–Marie–Tooth disease, FDA, Venetoclax, OHSU, Innovation, National Cancer Institute, BPD, Development, IND, CNS, NET, Schizophrenia, EVOLUTION, JHU, Azacitidine, NCI, FCCC, Deficit spending, IP, Paclitaxel, IIS, Food, European Patent Convention, CMT, Borderline personality disorder, Communication, Conference, AML, Aggression, Convertible bond, FMS, ALS, Phase, Kabuki syndrome, HOPE, Safety, SCLC, DSM-IV codes, EMA, Clinical trial, Medicine, EPO, Investigational New Drug, Duration, Platinum, Bangladesh Technical Education Board, Phase II, MRD, ICIS, MSKCC, Disease, Measure (mathematics), CRADA, Dor, Patent, HDAC6, Data analysis, Genomics, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the first quarter.
  • Research and development (R&D) expenses were $2.6 million for the quarter ended March 31, 2024, compared to $4.4 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $0.9 million for the quarter ended March 31, 2024, compared to $1.2 million for the quarter ended March 31, 2023.
  • Net losses were $1.1 for the quarter ended March 31, 2024, respectively, compared to $1.4 million for the quarter ended March 31, 2023.

Supmea Unveils Instrument Cloud at Hannover Messe, Highlighting Digitalization and Efficiency in Industrial Solutions

Retrieved on: 
星期一, 四月 29, 2024
Cloud, Exhibition, Measure (mathematics), Temperature, Hall, Internet of things, Water

HANNOVER, Germany, April 29, 2024 /PRNewswire/ -- Supmea, a renowned leader in self-developed and self-produced instrumentation technologies, is showcasing its latest breakthrough at Hannover Messe—the Instrument Cloud.

Key Points: 
  • HANNOVER, Germany, April 29, 2024 /PRNewswire/ -- Supmea, a renowned leader in self-developed and self-produced instrumentation technologies, is showcasing its latest breakthrough at Hannover Messe—the Instrument Cloud.
  • This state-of-the-art platform marks a significant advancement in the digitalization of industrial processes, offering smarter and more efficient solutions accessible via a mobile device app.
  • Since its first showcase in 2017, Supmea has been a consistent presence at the world's leading industrial event, now marking its seventh consecutive year.
  • Nate Ye, COO of Supmea, remarked that the integration of cloud technology and AI in industrial applications was a forefront topic at the exhibition.

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
星期一, 二月 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023

Retrieved on: 
星期五, 十二月 8, 2023
Bone marrow, Prednisone, Daratumumab, Consolidation, National Cancer Institute, ASH, NCI, Research and development, Measure (mathematics), VMP, Acute lymphoblastic leukemia, Ageing, Exposition, ECOG, Phase, Society, Relapse, Bangladesh Technical Education Board, AMGN, Amgen, Pharmaceutical industry, Nursing, Flour, Medical imaging, Veterinary medicine, Communications satellite, Blinatumomab, Research, Lenalidomide, Patient, Dexamethasone, Carfilzomib

THOUSAND OAKS, Calif., Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.

Key Points: 
  • THOUSAND OAKS, Calif., Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
  • "Data at this year's ASH meeting illustrate the expanding potential of our innovative hematology medicines, BLINCYTO and KYPROLIS, as well as our commitment to providing additional treatment options with our biosimilar eculizumab," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "As the pioneer of T-cell engager technology and building on nearly a decade of real-world experience, we continue to advance our first-in-class BiTE® molecule, BLINCYTO, into earlier lines of treatment where we have seen encouraging data in patients living with acute lymphoblastic leukemia."
  • Preliminary Results of the Gimema ALLL2820 Trial
    Abstract # 4249 , Session #614, Monday, December 11 from 6:00 - 8:00 p.m. PT
    *E1910 is sponsored by National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by the NCI Funded National Clinical Trial Network.

ORYZON Reports Financial Results and Corporate Updates for Quarter Ended September 30, 2023

Retrieved on: 
星期五, 十月 27, 2023
Research, ORY, Fruit, DMC, Food, Deficit spending, Risk, Medicine, ECNP, Schizophrenia, Platinum, ICMJE recommendations, SCLC, Charcot–Marie–Tooth disease, Sciatic nerve, Psychotherapy, Paclitaxel, NET, FCCC, MRD, Safety, EVOLUTION, BPD, Kabuki syndrome, Patient, Borderline personality disorder, ALS, Fox Chase Cancer Center, Genomics, Human, Duration, Glomus tumor, Measure (mathematics), Clinical trial, Dor, DSM-IV codes, Animal, European College of Neuropsychopharmacology, LSD1, FMS, CMT, FDA, IND, Innovation, ISIN, CNS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, HOPE, AML, Failure, Medical device, Pharmaceutical industry, Nursing, Cryptocurrency, EU, Science

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the third quarter.
  • The company has started a structured dialogue with corporate pharma to identify a suitable partner to move forward the asset to Phase III, pending positive results.
  • General and administrative expenses were $0.7 and $2.9 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.3 million for the quarter and nine months ended September 30, 2022.
  • Net losses were $0.8 and $3.4 million for the quarter and nine months ended September 30, 2023, respectively, compared to $0.7 and $3.9 million for the quarter and nine months ended September 30, 2022.

Kanbanize Becomes Businessmap, Launches End-to-End Business Agility Solution with Key Acquisition

Retrieved on: 
星期二, 十月 3, 2023
Software as a service, Partnership, Measure (mathematics), Acquisition, Kanban board, Business agility, Initiative, Software, Sales, Management, Agile

SOFIA, Bulgaria, Oct. 3, 2023 /PRNewswire/ -- Kanbanize transforms into Businessmap, reflecting a bold shift in focus towards tailored, holistic solutions. Through the acquisition of Berriprocess Agility, Businessmap establishes itself as the A+ Business Agility platform navigating companies from end-to-end, helping them align goals and deliver quality work faster.

Key Points: 
  • SOFIA, Bulgaria, Oct. 3, 2023 /PRNewswire/ -- Kanbanize transforms into Businessmap, reflecting a bold shift in focus towards tailored, holistic solutions.
  • Through the acquisition of Berriprocess Agility, Businessmap establishes itself as the A+ Business Agility platform navigating companies from end-to-end, helping them align goals and deliver quality work faster.
  • The new company name symbolizes its dedication to guiding enterprises towards evolving their business agility.
  • A pivotal milestone adds to the importance of the rebrand and completes the move towards being a holistic agility solution.

Kanbanize Becomes Businessmap, Launches End-to-End Business Agility Solution with Key Acquisition

Retrieved on: 
星期二, 十月 3, 2023
Software as a service, Partnership, Measure (mathematics), Acquisition, Kanban board, Business agility, Initiative, Software, Sales, Management, Agile

SOFIA, Bulgaria, Oct. 3, 2023 /PRNewswire/ -- Kanbanize transforms into Businessmap, reflecting a bold shift in focus towards tailored, holistic solutions. Through the acquisition of Berriprocess Agility, Businessmap establishes itself as the A+ Business Agility platform navigating companies from end-to-end, helping them align goals and deliver quality work faster.

Key Points: 
  • SOFIA, Bulgaria, Oct. 3, 2023 /PRNewswire/ -- Kanbanize transforms into Businessmap, reflecting a bold shift in focus towards tailored, holistic solutions.
  • Through the acquisition of Berriprocess Agility, Businessmap establishes itself as the A+ Business Agility platform navigating companies from end-to-end, helping them align goals and deliver quality work faster.
  • The new company name symbolizes its dedication to guiding enterprises towards evolving their business agility.
  • A pivotal milestone adds to the importance of the rebrand and completes the move towards being a holistic agility solution.

Emerson Expands Automation Leadership With Agreement to Acquire Flexim

Retrieved on: 
星期三, 八月 16, 2023
Measure (mathematics), Culture, Gas, EBITA, Analytic, Steam, Water, Growth, NYSE, Ultrasonic flow meter, Retail, Coriolis, Evercore

ST. LOUIS, Aug. 16, 2023 /PRNewswire/ -- Emerson (NYSE: EMR) today announced a definitive agreement to acquire FLEXIM Flexible Industriemeßtechnik GmbH ("Flexim"), a global leader in clamp-on ultrasonic flow measurement for liquids, gases and steam.

Key Points: 
  • ST. LOUIS, Aug. 16, 2023 /PRNewswire/ -- Emerson (NYSE: EMR) today announced a definitive agreement to acquire FLEXIM Flexible Industriemeßtechnik GmbH ("Flexim"), a global leader in clamp-on ultrasonic flow measurement for liquids, gases and steam.
  • Headquartered in Berlin, Germany, Flexim brings highly differentiated, complementary technology and strong customer relationships to Emerson, with an installed base of more than 100,000 flowmeters, as well as approximately 450 employees.
  • Flexim provides highly accurate, low-maintenance clamp-on ultrasonic flow measurement technology for a broad range of attractive end markets, including chemical, water & wastewater, life sciences, food & beverage, and power generation.
  • The transaction will expand Emerson's automation portfolio and measurement capabilities, complementing its existing flow measurement positions in Coriolis, differential pressure, magmeter and vortex flow measurement.

Therap's Enhanced Features Offers Users to Document an Individual's Behavior Data, Significant Life Events and Ability to Create Behavior Plans

Retrieved on: 
星期二, 八月 8, 2023
Measure (mathematics), Medicaid Home and Community-Based Services Waivers, Electronic health record, Service, LTSS, Organization, Behavior, Caregiver, Management

This feature allows service users working with individuals to easily record behavior events that happen infrequently or regularly.

Key Points: 
  • This feature allows service users working with individuals to easily record behavior events that happen infrequently or regularly.
  • For unanticipated behavior events, staff may choose from the configured list of behaviors and interventions that the specialist or doctors have identified.
  • The Significant Life Event(s) feature is a separate component that allows users to document and track significant events experienced by individuals.
  • The Behavior Plan Data and Significant Life Event(s) features aim to assist users in effectively recording, tracking, and summarizing behavior data and documenting significant events in order to better support individuals and analyze their progress over time.

ScopeFour Capital Launches Innovative Climate Impact Investment Platform

Retrieved on: 
星期五, 六月 2, 2023
Database, Framework, CFA, Head, ERP, Materiality, Carbon, Organization, Public expenditure, First Eagle Investments, Climate, Fine chemical, Renewable energy, Measure (mathematics), Climate change mitigation

EL SEGUNDO, Calif., June 2, 2023 /PRNewswire/ -- ScopeFour Capital ("ScopeFour" or "the Firm"), an innovative investment manager focused on investing in and accelerating climate solutions in public equity markets, today announced that it has launched its initial strategy. ScopeFour integrates its proprietary Climate Impact & Alpha framework into its investment process to identify companies poised to profit in the short- and long-term from the unavoidable global transition towards net zero.

Key Points: 
  • Invests in Decarbonization and Climate Solutions Leveraging Proprietary, Measurable, Science-led Framework
    EL SEGUNDO, Calif., June 2, 2023 /PRNewswire/ -- ScopeFour Capital ("ScopeFour" or "the Firm"), an innovative investment manager focused on investing in and accelerating climate solutions in public equity markets, today announced that it has launched its initial strategy.
  • ScopeFour integrates its proprietary Climate Impact & Alpha framework into its investment process to identify companies poised to profit in the short- and long-term from the unavoidable global transition towards net zero.
  • Leveraging metrics informed by science-led organizations CRANE and Project Drawdown, ScopeFour has established a proprietary climate classification system of over 100 climate solutions across six themes, which enables the Firm to rank investment opportunities by emission reduction potential (ERP) among other key climate and financial metrics.
  • "Implementing an active, fundamental-based approach to construct a diversified portfolio of climate impact leaders offers favorable risk-reward characteristics for investors – you don't need to sacrifice returns for impact.